What's new

Human medicines European public assessment report (EPAR): Prevenar 20 (previously Apexxnar), pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed), Date of authorisation: 14/02/2022, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Prevenar 20 (previously Apexxnar), pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed), Date of authorisation: 14/02/2022, Revision: 11, Status: Authorised

Apr 24, 2025 - 14:59
 0
Human medicines European public assessment report (EPAR): Prevenar 20 (previously Apexxnar), pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed), Date of authorisation: 14/02/2022, Revision: 11, Status: Authorised
Human medicines European public assessment report (EPAR): Prevenar 20 (previously Apexxnar), pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed), Date of authorisation: 14/02/2022, Revision: 11, Status: Authorised
Read More

Tags:

Previous Article

Auto Industry May Get A Much-Needed Break From Trump's Tariffs

Next Article

Despite Tariff Turmoil, Stellantis Aims Solid-State Battery Plan At US EV Market

Related Posts

Questions and answers clinic on post-authorisation procedure management in IRIS, Online, from 8 January 2025, 14:00 (CET) to 8 January 2025, 15:00 (CET)

Questions and answers clinic on post-authorisation proc...

Feb 9, 2025  0

Human medicines European public assessment report (EPAR): Litak, cladribine, Date of authorisation: 14/04/2004, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025  0

European Shortages Monitoring Platform (ESMP) data acce...

Mar 10, 2025  0